Comparisons

Price checked September 20, 2026: oral Wegovy and Foundayo each start at $149 for the medicine. Wegovy pill costs $149 at 1.5 mg, $199 at 4 mg and $299 at 9 or 25 mg through NovoCare; Foundayo has promotional 2.5 and 5.5 mg prices through December 2026. Their weight-loss results come from separate trials, not a head-to-head comparison.

Tirzepatide produced greater average weight loss in SURMOUNT-5, but the trial studied specific injections and doses in adults without diabetes. Compare that evidence with current formulations, medical indications and practical cost routes.

Updated August 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo with higher-dose pricing. Both may be as low as $25/mo for eligible commercially insured patients using a savings card.

Verified August 14, 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,027.51/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). NovoCare lists each pen at $199/mo for the first two low-dose fills; Wegovy then costs $349/mo at standard strengths ($399 HD), while Ozempic costs $349/mo at 0.25-1mg or $499/mo at 2mg. Pills start at $149/mo and are dose-dependent.

Mounjaro and Ozempic are different diabetes medicines. Tirzepatide produced greater average weight loss in specific trials, but the widely quoted 20.2% versus 13.7% result studied weight-management doses in adults without diabetes. Here is how that changes the comparison.

Verified July 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo, a program Mounjaro does not offer.

Updated September 20, 2026: Wegovy pill starts at $149 for 1.5 mg, rising to $199 at 4 mg and $299 at 9 or 25 mg. The pen's $199 low-dose offer is limited to the first two fills; later self-pay prices differ. The pill and injection weight-loss results come from separate trials, not a head-to-head test.